Onkológia 5/2018
Interference with NAT in the treatment of multiple myeloma by monoclonal antibody
Treatment of multiple myeloma currently survives dynamic development and brings new possibilities. The promising group of drugs are monoclonal antibodies, including daratumumab (DARA). This anti-CD38 antibody exhibits a very good therapeutic effect without significant concomitant toxicity. However, the CD38 antigen is also present on erythrocytes, so DARA also binds to it after application. It does not cause clinical or laboratory signs of hemolysis, but induces non-specific reactivity and interferes with pre-transfusion tests. Panagglutination caused by anti-CD38 during the indirect antiglobulin test may mask the presence of a clinically significant RBC alloantibodies. Therefore, the administration of the drug requires the observance of certain conditions and the awareness and close cooperation of myeloma specialist with hospital transfusion laboratories and blood banks that provide hemotherapy to patients with multiple myeloma.
Keywords: daratumumab, pre-transfusion immunohaematology testing, indirect anglobulin test, dithiotreitol












